BeiGene, Ltd. (NASDAQ:ONC) — Market Cap & Net Worth
Market Cap & Net Worth: BeiGene, Ltd. (ONC)
BeiGene, Ltd. (NASDAQ:ONC) has a market capitalization of $30.02 Billion ($30.02 Billion) as of May 2, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #884 globally and #376 in its home market, demonstrating a -1.98% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying BeiGene, Ltd.'s stock price $293.86 by its total outstanding shares 102149681 (102.15 Million). Analyse BeiGene, Ltd. cash flow conversion to see how efficiently the company converts income to cash.
BeiGene, Ltd. Market Cap History: 2025 to 2026
BeiGene, Ltd.'s market capitalization history from 2025 to 2026. Data shows growth from $31.03 Billion to $30.02 Billion (0.00% CAGR).
Index Memberships
BeiGene, Ltd. is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 1.24% | #10 of 976 |
Weight: BeiGene, Ltd.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
BeiGene, Ltd. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how BeiGene, Ltd.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
5.81x
BeiGene, Ltd.'s market cap is 5.81 times its annual revenue
Latest Price to Earnings (P/E) Ratio
108.16x
BeiGene, Ltd.'s market cap is 108.16 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2025 | $31.03 Billion | $5.34 Billion | $286.93 Million | 5.81x | 108.16x |
Competitor Companies of ONC by Market Capitalization
Companies near BeiGene, Ltd. in the global market cap rankings as of May 2, 2026.
Key companies related to BeiGene, Ltd. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
BeiGene, Ltd. Historical Marketcap From 2025 to 2026
Between 2025 and today, BeiGene, Ltd.'s market cap moved from $31.03 Billion to $ 30.02 Billion, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $30.02 Billion | -3.28% |
| 2025 | $31.03 Billion | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of BeiGene, Ltd. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $30.02 Billion USD |
| MoneyControl | $30.02 Billion USD |
| MarketWatch | $30.02 Billion USD |
| marketcap.company | $30.02 Billion USD |
| Reuters | $30.02 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About BeiGene, Ltd.
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatm… Read more